ArticleCase reports in immunology2026
False Elevation of Parathyroid Hormone in a Patient With Lung Metastasis of Rectal Cancer After Immunotherapy: A Case Report and Literature Review.
Article in Case reports in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- False Elevation of Parathyroid Hormone in a Patient With Lung Metastasis of Rectal Cancer After Immunotherapy: A Case Report and Literature Review.Case reports in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunoassays are commonly used in clinical laboratories to measure a variety of analytes, including hormones and tumor markers. Interference caused by rheumatoid factor (RF), heterophile antibodies, and human anti-animal antibodies (HAAA) has been reported but is rarely identified in daily practice. Here, we report a case of falsely elevated parathyroid hormone (PTH) due to immunoassay interference and review the literature. Case Presentation: A 57-year-old man who recovered well from lung metastasis of rectal cancer treated with bevacizumab and sintilimab for 1 year, presented to Peking University People's Hospital with persistently high PTH levels (>1200 ng/L) measured by a Roche Elecsys assay. He had hypoadrenocorticism induced by anti-programmed cell death 1 (PD-1), normal renal function, normal total calcium level, and normal 25-OH vitamin D concentration. The Beckman Coulter UniCel DxI 800 and Siemens Immulite 2000 platforms measured PTH levels of 18.3 ng/L and 8.7 ng/L, respectively. After the patient's serum was treated with polyethylene glycol (PEG) precipitation or mouse serum, the PTH levels determined by the Roche immunoassay decreased to 56.5 ng/L and 265.3 ng/L, respectively. Conclusion: Interference due to human anti-mouse antibodies (HAMA) could be the cause of falsely elevated PTH in the patient. Physicians should realize that immunoassay interference can lead to false results and closely communicate with the laboratory to avoid misdiagnosis and inappropriate therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.